PloS one · 2026
Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mukherjee Anindya, Goyal Pankaj, Tripathi Rupal, Goyal Sumit, Batra Ullas, Talwar Vineet, Goel Varun, Jain Arpit, Saha Shekhar, Bothra Sneha, Agrawal Chaturbhuj, Chugh Swati, Doval Dinesh Chandra
Аннотация
BACKGROUND: The present study evaluated the real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR + /HER2-) metastatic breast cancer.
METHOD: This study was conducted on the HR + /HER2- metastatic breast cancer patients who received palbociclib/ ribociclib in the first line or recurrent setting between January 2021 and January 2023 along with endocrine therapy. Data was retrieved from the Hospital medical records.
RESULTS: In the patients receiving palbociclib, a better median progression free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). Similarly, in the patients receiving ribociclib, a better median PFS was observed in patients with ECOG PS 1 (22.2 months,p-value <0.0001), de novo disease (21.7 months,p-value 0.0042), first-line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (21.7 months,p-value <0.0001). On multivariate analysis, ECOG PS, line of hormone therapy and prior chemotherapy showed significance (p-values <0.0001, < 0.0001 & 0.0269, respectively).
CONCLUSION: The study shows real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in metastatic breast cancer in India.
METHOD: This study was conducted on the HR + /HER2- metastatic breast cancer patients who received palbociclib/ ribociclib in the first line or recurrent setting between January 2021 and January 2023 along with endocrine therapy. Data was retrieved from the Hospital medical records.
RESULTS: In the patients receiving palbociclib, a better median progression free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). Similarly, in the patients receiving ribociclib, a better median PFS was observed in patients with ECOG PS 1 (22.2 months,p-value <0.0001), de novo disease (21.7 months,p-value 0.0042), first-line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (21.7 months,p-value <0.0001). On multivariate analysis, ECOG PS, line of hormone therapy and prior chemotherapy showed significance (p-values <0.0001, < 0.0001 & 0.0269, respectively).
CONCLUSION: The study shows real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in metastatic breast cancer in India.